Trials / Completed
CompletedNCT00575913
Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study
ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess, under daily practice conditions, the safety profile and the efficacy of a new formulation of alfuzosin administered once daily (Xatral XL) in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alfuzosin | Alfuzosin 10 mg One tablet per day after evening meal |
Timeline
- Start date
- 2003-09-01
- Completion
- 2005-03-01
- First posted
- 2007-12-18
- Last updated
- 2008-04-10
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT00575913. Inclusion in this directory is not an endorsement.